Related Experiment Video
Updated: Aug 11, 2026
11:25
Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
Myelofibrosis: response to busulfan after hydroxyurea failure
1Department of Medicine, Wright State University School of Medicine, Dayton, Ohio 45428, USA.
International Journal of Clinical Practice
|June 21, 2002
Summary
Myelofibrosis with myeloid metaplasia (MMM) dramatically responded to oral busulfan after hydroxyurea failure. This suggests busulfan may be a viable treatment option for MMM when other therapies fail or are not tolerated.
Area of Science:
- Hematology
- Oncology
Background:
- Myelofibrosis with myeloid metaplasia (MMM) is a myeloproliferative neoplasm.
- Current treatments include hydroxyurea and interferon-alpha.
Observation:
- A patient with MMM experienced a significant positive response to oral busulfan.
- This response occurred after the patient's condition did not improve with hydroxyurea therapy.
Findings:
- Oral busulfan demonstrated dramatic efficacy in a patient with MMM refractory to hydroxyurea.
- This case highlights the potential effectiveness of busulfan in specific MMM patient populations.
Implications:
- Busulfan may represent a valuable therapeutic option for MMM patients who fail or cannot tolerate standard treatments like hydroxyurea or interferon-alpha.
- Further investigation into busulfan's role in managing refractory MMM is warranted.
